Oncology

3
Pipeline Programs
9
Companies
7
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
3
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1100%
+ 6 programs with unclassified modality

Competitive Landscape

7 companies ranked by most advanced pipeline stage

AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
1 program
1
AZD9291Phase 11 trial
Active Trials
NCT02491944Completed27Est. Aug 2015
GS
Gilead SciencesFOSTER CITY, CA
1 program
1
EntospletinibPhase 1Small Molecule1 trial
Active Trials
NCT02521376Completed56Est. Oct 2017
Nested Therapeutics
Nested TherapeuticsMA - Cambridge
1 program
1
NST-628Phase 11 trial
Active Trials
NCT06326411Recruiting230Est. Nov 2029
M&
Merck & Co.RAHWAY, NJ
1 program
ChemotherapyN/A1 trial
Active Trials
NCT05364905Completed200Est. Nov 2022
Roche
RocheSTAVANGER NORWAY, Norway
1 program
NAVIFY Oncology HubN/A1 trial
Active Trials
NCT05478135Completed27Est. Nov 2022
T-Therapeutics
T-TherapeuticsUK - Cambridge
1 program
indwelling device biofilm identificationN/A1 trial
Active Trials
NCT04328818UnknownEst. Oct 2025
City Therapeutics
City TherapeuticsMA - Cambridge
1 program
low-flow anesthesiaN/A1 trial
Active Trials
NCT06430593Not Yet RecruitingEst. Jan 2025

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
Nested TherapeuticsNST-628
Gilead SciencesEntospletinib
AstraZenecaAZD9291
City Therapeuticslow-flow anesthesia
RocheNAVIFY Oncology Hub
Merck & Co.Chemotherapy
T-Therapeuticsindwelling device biofilm identification

Clinical Trials (7)

Total enrollment: 540 patients across 7 trials

NCT06326411Nested TherapeuticsNST-628

A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors

Start: Apr 2024Est. completion: Nov 2029230 patients
Phase 1Recruiting
NCT02521376Gilead SciencesEntospletinib

Pharmacokinetics of Entospletinib in Adults With Normal and Impaired Liver Function

Start: Nov 2015Est. completion: Oct 201756 patients
Phase 1Completed
NCT02491944AstraZenecaAZD9291

A Phase I, Open-label Study to Assess Bioavailability of a Single Oral Dose of AZD9291 vs an IV Dose of [14C]AZD9291

Start: Jul 2015Est. completion: Aug 201527 patients
Phase 1Completed
NCT06430593City Therapeuticslow-flow anesthesia

Evaluation of Low Flow and Normal Flow Anesthesia Management in Robotic Assisted Laparoscopic Surgeries

Start: Aug 2024Est. completion: Jan 2025
N/ANot Yet Recruiting
NCT05478135RocheNAVIFY Oncology Hub

A Remote Evaluation of NAVIFY Oncology Hub Using Clinical Simulation

Start: May 2022Est. completion: Nov 202227 patients
N/ACompleted
NCT05364905Merck & Co.Chemotherapy

Patients Characteristics, Treatment Pattern & Outcomes of Patients With Advanced, Recurrent or Metastatic Endometrial Carcinoma

Start: May 2022Est. completion: Nov 2022200 patients
N/ACompleted
NCT04328818T-Therapeuticsindwelling device biofilm identification

Indwelling Device-associated Biofilms

Start: Jun 2019Est. completion: Oct 2025
N/AUnknown

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 540 patients
9 companies competing in this space